Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Adds Osteoporosis Claim For Reclast, Plans Prevention Filing By Year End

Executive Summary

Novartis plans to file an osteoporosis prevention claim for Reclast (zoledronic acid) by the end of 2007, the company told "The Pink Sheet" after the bisphosphonate's Aug. 17 approval for osteoporosis treatment. The Swiss firm will seek an indication for prevention of clinical fractures after hip fracture in both men and women
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS048723

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel